×
A pragmatic randomized controlled trial reports lack of efficacy of hydroxychloroquine ...
https://doi.org/10.1038/s41467-020-19056-6
Nature Communications; Lyngbakken MN, Berdal JE et. al.

Oct 21st, 2020 - Here, we randomized 53 patients hospitalized with coronavirus disease 2019 (COVID-19) to hydroxychloroquine therapy (at a dose of 400 mg twice daily for seven days) in addition to standard care or standard care alone (ClinicalTrials.gov Identifier, NCT04316377). All severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive patients 18 years of age or older were eligible for study in...

The Outcome of Hydroxychloroquine in Patients Treated for COVID-19: Systematic Review a...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7556078
Canadian Respiratory Journal; Ayele Mega T, Feyissa TM et. al.

Oct 21st, 2020 - The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) resulted in an unprecedented public health challenge worldwide. Despite urgent and extensive global efforts, the existing evidence is inconclusive regarding the medications used for the treatment of COVID-19. To generate an up-to-date evidence for the clinical safety and ef...

The Cross-Talk between Age, Hypertension and Inflammation in COVID-19 Patients: Therape...
https://doi.org/10.1007/s40266-020-00808-4
Drugs & Aging; Casucci G, Acanfora D et. al.

Oct 21st, 2020 - This paper presents a brief overview of the complex interaction between age, hypertension, the renin-angiotensin-aldosterone system (RAAS), inflammation, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) infection. Coronavirus disease 2019 (COVID-19) is more frequent and more severe in comorbid elderly patients, especially those with hypertension, diabetes, obesity, or cardiovascu...

Management of lung transplantation in the COVID-19 era - An international survey.
https://doi.org/10.1111/ajt.16368
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons; Coiffard B, Lepper PM et. al.

Oct 21st, 2020 - It is unknown if solid organ transplant recipients are at higher risk for severe COVID-19. The management of a lung transplantation (LTx) program and the therapeutic strategies to adapt the immunosuppressive regimen and antiviral measures is a major issue in the COVID-19 era, but little is known about worldwide practice. We sent out to 180 LTx centers worldwide in June 2020 a survey with 63 que...

Coronavirus disease 2019 (COVID-19) in the heart transplant population: a single-centre...
https://doi.org/10.1093/ejcts/ezaa323
European Journal of Cardio-thoracic Surgery : Official Journal of the European Association for Cardio-thoracic Surgery; Caraffa R, Bagozzi L et. al.

Oct 21st, 2020 - Few anecdotal cases have been reported in the literature regarding heart transplant recipients and infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We report our experience with 6 patients hospitalized in Northern Italy during the outbreak. Of the 396 living heart transplant recipients from 1985 to 2020 included in the study, 6 patients developed the novel 2019 coron...

Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A...
https://doi.org/10.1007/s40264-020-01013-3
Drug Safety; Garcia P, Revet A et. al.

Oct 20th, 2020 - Psychiatric Disorders and Hydroxychloroquine for Coronavirus Disease 2019 (COVID-19): A VigiBase Study.|2020|Garcia P,Revet A,Yrondi A,Rousseau V,Degboe Y,|

Hydroxychloroquine Safety Outcome within Approved Therapeutic Protocol for COVID-19 Out...
https://doi.org/10.1016/j.ijid.2020.10.031
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases; Mohana A, Sulaiman T et. al.

Oct 19th, 2020 - Global healthcare is challenged following the COVID-19 pandemic, since late 2019. Multiple approaches have been performed to relieve the pressure and support existing healthcare. The Saudi Arabian Ministry of Health (MOH) launched an initiative to support the National Healthcare System. Since the 5th of June 2020, 238 outpatient fever clinics were established nationwide. This study aimed to ass...

Management of Irrational Self-Purchase of Hydroxychloroquine During the COVID-19 Pandem...
https://doi.org/10.1097/HCO.0000000000000816
Journal of Patient Safety; Shao SC, Lai EC et. al.

Oct 19th, 2020 - There is an increasing recognition that structural abnormalities and functional changes in the placenta can have deleterious effects on the development of the fetal heart. This article reviews the role of the placenta and the potential impact of placental insufficiency on fetuses with congenital heart disease. The fetal heart and the placenta are directly linked because they develop concurrentl...

Preparation and physicochemical stability of 50 mg/ml hydroxychloroquine oral suspensio...
https://doi.org/10.1016/j.ijantimicag.2020.106201
International Journal of Antimicrobial Agents; Binson G, Venisse N et. al.

Oct 19th, 2020 - In the context of the SARS-CoV-2 pandemic, hydroxychloroquine has been proposed as a potential agent to treat COVID-19 patients. Older adults are more susceptible to COVID-19 and some patients may require admission in intensive care units, where oral drug administration of solid forms may be compromised in many COVID-19 patients. However, liquid formulation of hydroxychloroquine is not commerci...

Hydroxychloroquine as pre-exposure prophylaxis for COVID-19 in healthcare workers: a ra...
https://doi.org/10.1093/cid/ciaa1571
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America; Rajasingham R, Bangdiwala AS et. al.

Oct 17th, 2020 - Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a rapidly emerging virus causing the ongoing Covid-19 pandemic with no known effective prophylaxis. We investigated whether hydroxychloroquine could prevent SARS-CoV-2 in healthcare workers at high risk of exposure. We conducted a randomized, double-blind, placebo-controlled clinical trial of healthcare workers with ongoing exposur...

Clinical management of Lupus patients during the COVID-19 pandemic.
https://doi.org/10.1177/0961203320961848
Lupus Mason A, Rose E et. al.

Oct 16th, 2020 - Severe acute respiratory syndrome coronavirus (SARS-CoV-2), the virus causing Coronavirus disease 2019 (COVID-19), has had a huge impact on health services with a high mortality associated with complications including pneumonia and acute respiratory distress syndrome. Historical evidence suggests that Lupus patients have a higher incidence of several viral infections. This is likely due to a co...

QTc prolongation among hydroxychloroquine sulfate-treated COVID-19 patients: An observa...
https://doi.org/10.1111/ijcp.13767
International Journal of Clinical Practice; Fteiha B, Karameh H et. al.

Oct 16th, 2020 - The liberal administration of hydroxychloroquine-sulphate (HCQ) to COVID-19 patients has raised concern regarding the risk of QTc prolongation and cardiac arrhythmias, particularly when prescribed with azithromycin. We evaluated the incidence of QTc prolongation among moderately and severely ill COVID-19 patients treated with HCQ and of the existence of concomitant alternative causes. All COVID...

Elucidating the Pivotal Immunomodulatory and Anti-Inflammatory Potentials of Chloroquin...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7533005
Journal of Immunology Research; Richard SA, Kampo S et. al.

Oct 16th, 2020 - Chloroquine (CQ) and hydroxychloroquine (HCQ) are derivatives of 4-aminoquinoline compounds with over 60 years of safe clinical usage. CQ and HCQ are able to inhibit the production of cytokines such as interleukin- (IL-) 1, IL-2, IL-6, IL-17, and IL-22. Also, CQ and HCQ inhibit the production of interferon- (IFN-) α and IFN-γ and/or tumor necrotizing factor- (TNF-) α. Furthermore, CQ blocks the...

Cardiac Complications Attributed to Hydroxychloroquine: A systematic review of the Lite...
https://doi.org/10.2174/1573403X16666201014144022
Current Cardiology Reviews; Fram G, Wang DD et. al.

Oct 16th, 2020 - Hydroxychloroquine has been used for rheumatological diseases for many decades and is considered a safe medication. With the COVID-19 outbreak, there has been an increase in reports associating cardiotoxicity with hydroxychloroquine. It is unclear if cardiotoxic profile of hydroxychloroquine is previously underreported in the literature, or a new manifestation of COVID-19 and therapeutic interv...

Use of Ivermectin is Associated with Lower Mortality in Hospitalized Patients with COVI...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7550891
Chest Rajter JC, Sherman MS et. al.

Oct 16th, 2020 - Ivermectin was shown to inhibit SARS-CoV-2 replication in-vitro, which has led to off-label use, but clinical efficacy has not been previously described. Does ivermectin benefit hospitalized COVID-19 patients? and Methods: Charts of consecutive patients hospitalized at four Broward Health hospitals in Florida with confirmed COVID-19 between March 15 through May 11, 2020 treated with or without ...

How the COVID-19 pandemic has influenced pediatric rheumatology practice: Results of a ...
https://doi.org/10.1016/j.semarthrit.2020.09.008
Seminars in Arthritis and Rheumatism; Batu ED, Lamot L et. al.

Oct 16th, 2020 - The COVID-19 pandemic is a global health problem. We, as the EMERGE (EMErging RheumatoloGists and rEsearchers) group of PReS (Pediatric Rheumatology European Society) analyzed how the pandemic has affected pediatric rheumatology practice. An online survey was developed to assess changes in pediatric rheumatology practice due to the pandemic. Results were analyzed using descriptive statistics. F...

Medications prescriptions in COVID-19 pregnant and lactating women: the Bergamo Teratol...
https://doi.org/10.1515/jpm-2020-0339
Journal of Perinatal Medicine; Giampreti A, Eleftheriou G et. al.

Oct 15th, 2020 - Objectives The severe acute respiratory syndrome coronavirus 2 (COVID-19) outbreak in Italy, especially in Lombardy and Bergamo city, represented probably nowadays one of the first major clusters of COVID-19 in the world. The aim of this report is to describe the activity of Bergamo Teratology Information Service (TIS) in supporting the public and health-care personnel in case of drug prescript...

The first wave of COVID-19 in Malta; a national cross-sectional study.
https://doi.org/10.1371/journal.pone.0239389
PloS One; Micallef S, Piscopo TV et. al.

Oct 15th, 2020 - The COVID-19 pandemic has posed major challenges to all aspects of healthcare. Malta's population density, large proportion of elderly and high prevalence of diabetes and obesity put the country at risk of uncontrolled viral transmission and high mortality. Despite this, Malta achieved low mortality rates compared to figures overseas. The aim of this paper is to identify key factors that contri...

COVID-19 And Type 2 Diabetes Mellitus: Hydroxychloroquine May Be The Holy Grail.
https://doi.org/10.2174/1871526520666201013160803
Infectious Disorders Drug Targets; Pal R, Bhasin MK et. al.

Oct 14th, 2020 - The novel coronavirus disease (COVID-19) is on the rampage claiming over 297000 lives globally. Disease severity and mortality rates are higher in patients with underlying diabetes mellitus. Till date, there exists no effective vaccine or therapy against COVID-19. However, with limited clinical data, hydroxychloroquine is being used for treatment and prophylaxis in patients with COVID-19. Hydro...

Identify potent SARS-CoV-2 main protease inhibitors via accelerated free energy perturb...
https://doi.org/10.1073/pnas.2010470117 10.1101/2020.05.21.108605
Proceedings of the National Academy of Sciences of the United States of America; Li Z, Li X et. al.

Oct 14th, 2020 - The COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become a global crisis. There is no therapeutic treatment specific for COVID-19. It is highly desirable to identify potential antiviral agents against SARS-CoV-2 from existing drugs available for other diseases and thus repurpose them for treatment of COVID-19. In general, a drug repurposing effort ...